Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection

Arthritis and Rheumatism

Volumn 48, Issue 7, 2003, Pages 1939-1947

  Von Landenberg, Philipp ^a,b   Lehmann, Hartwig W ^c,d   Knöll, Antje ^e   Dorsch, Simone ^e   Modrow, Susanne ^f  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Abt fur Padiatrische Rheumatologie   (Germany)

^d Sachsisches Krankenhaus Hubertusburg   (Germany)

^e MORPHOSYS AG   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BONE DISEASE; CHILD; DISEASE ASSOCIATION; FEMALE; GROWTH RETARDATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PARVOVIRUS; PERSISTENT INFECTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VIREMIA; VIRUS GENOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, VIRAL; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; RHEUMATIC DISEASES; SEROEPIDEMIOLOGIC STUDIES;

EID: 0038681410     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11038     Document Type: Article

References (65)

1. Brown KE. Human parvovirus B19 epidemiology and clinical manifestations. In: Anderson LJ, Young NS, editors. Human parvovirus B19. Monographs in virology. Vol. 20. Basel: Karger; 1997. p. 42-60.
2. Cherry JD. Parvovirus infections in children and adults. Adv Pediatr 1999;46:245-69.
3. Török TJ. Unusual clinical manifestations reported in patients with parvovirus B19 infection. In: Anderson LJ, Young NS, editors. Human parvovirus B19. Monographs in virology. Vol. 20. Basel: Karger; 1997. p. 61-92.
4. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Blase RM, et al. Chronic bone marrow failure due to persistent parvovirus B19 infection. N Engl J Med 1987;317:287-94.
5. Pont J, Puchhammer-Stöckl E, Chott A, Popow-Kraupp T, Kienzer I, Postner G, et al. Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 1992;80:160-5.
6. Ozawa K, Young N. Characterisation of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol 1987;62:2508-11.
7. Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063-5.
8. Cassinotti P, Siegl G, Michel BA, Bruhlmann P. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J Med Virol 1998;56:199-204.
9. Agbandje-McKenna M, Rossmann MG. The structure of human parvovirus B19. In: Anderson LJ, Young NS, editors. Human parvovirus B19. Monographs in virology. Vol. 20. Basel: Karger; 1997. p. 3-15.
10. Zadori Z, Szelei J, Lacoste MC, Li Y, Gariepy S, Raymond P, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001;291-302.
11. Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002;76:2014-8.
12. Kurtzman GJ, Cohen B, Hanson G, Field AM, Oseas R, Blase RM, et al. Immune response to parvovirus B19 and an antibody defect in persistent viral infection. J Clin Invest 1989;84:1114-23.
13. Kurtzman GJ, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23.
14. Moffat S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural protein induces apoptosis in erythroid lineage cells. J Virol 1998;72:3018-28.
15. Gareus R, Gigler A, Hemauer A, Leruez-Ville M, Morinet F, Wolf H, et al. Characterization of cis-acting and NS1-responsive elements in the p6 promoter of parvovirus B19. J Virol 1998;72:609-16.
16. Raab U, Bauer B, Gigler A, Beckenlehner K, Wolf H, Modrow S. Cellular transcription factors that interact with p6 promoter elements of parvovirus B19. J Gen Virol 2001;82:1473-80.
17. Von Poblotzki A, Hemauer A, Gigler A, Puchhammer-Stöckl E, Heinz FX, Pont J, et al. Detection of antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 1995;172:1356-9.
18. Hemauer A, Modrow S, Georgi J, Helmke K, Veith P, Lang B, et al. There is no correlation between polymyalgia rheumatica and acute parvovirus B19 infection [letter]. Ann Rheum Dis 1999;58:657.
19. Kerr JR, Cuniffe VS. Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection. Rheumatology 2000;39:903-8.
20. Zakrzewska K, Azzi A, De Biasi E, Radossi P, De Santis R, Davoli PG, et al. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001;65:402-7.
21. Lehmann HW, Kühner L, Beckenlehner K, Müller-Godeffroy E, Heide KG, Küster RM, et al. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. J Clin Virol 2002;25:135-43.
22. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
23. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;26:1211-4.
24. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
25. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992;148:3885-91.
26. Shoenfeld Y, Gharavi A, Koike T. β2GP-I in the antiphospholipid (Hughes') syndrome - from a cofactor to an autoantigen - from induction to prevention of antiphospholipid syndrome. Lupus 1998;7:503-6.
27. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992;90:1105-9.
28. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441-55.
29. George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A, et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998;97:900-6.
30. Loizou SA, Walport MJ, Davies KA. The antiphospholipid syndrome in infectious diseases. In: The antiphospholipid syndrome. Asherson R, Cervera R, Piette JC, Shoenfeld Y, editors. Andover (UK): CRC Press; 1996. p. 267-84.
31. Puri V, Bookman A, Yeo E, Cameron R, Heathcote EJ. Antiphospholipid antibody syndrome associated with hepatitis C infection. J Rheumatol 1999;26:509-10.
32. Yanez A, Cedillo L, Neyrolles O, Alonso E, Prevost MC, Rojas J, et al. Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome. Emerg Infect Dis 1999;5:164-7.
33. Hayem G, Kassis N, Nicaise P, Bouvet P, Andremont A, Labarre C, et al. Systemic lupus erythematosus-associated catastrophic antiphospholipid syndrome occurring after typhoid fever: a possible role of Salmonella lipopolysaccharide in the occurrence of diffuse vasculopathy-coagulopathy. Arthritis Rheum 1999;42:1056-61.
34. Shoenfeld Y, Blank M, Krause I. The relationship of antiphospholipid antibodies to infections: do they bind to infecting agents or may they even be induced by them? Clin Exp Rheumatol 2000;18:431-2.
35. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-77.
36. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109;797-804.
37. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998;12:1255-65.
38. Karlsen AE, Dyrberg T. Molecular mimicry between nonself, modified self and self in autoimmunity. Semin Immunol 1998;10:25-34.
39. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-74.
40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-23.
41. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. J Rheumatol 1998;25:1991-3.
42. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
43. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
44. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
45. Knöll A, Louwen F, Kochanowski B, Plentz A, Stüssel J, Beckenlehner K, et al. Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). J Med Virol 2002;67:259-66.
46. Koch WC. Parvovirus B19. In: Behrman RE, Kliegman RM, Jenson HB, editors. Textbook of pediatrics. 16th ed. Philadelphia: Saunders; 2000. p. 964-6.
47. Hemauer A, Gigler A, Searle K, Beckenlehner K, Raab U, Broliden K, et al. Seroprevalence of parvovirus B19 NS1-specific IgG in B19 infected and uninfected individuals and in infected pregnant women. J Med Virol 2000;60:48-55.
48. Lehmann HW, Knöll A, Küster R-M, Modrow S. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. Arthritis Rheum. In press.
49. Trapani S, Ermini M, Falcini F. Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Semin Arthritis Rheum 1999;28:319-25.
50. Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997;53:229-32.
51. Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000;19:886-7.
52. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, et al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997;96:3549-54.
53. Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D'Amati G, et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Commun Infect Dis 2000;31:65-9.
54. Eis-Hübinger AM, Reber U, Abdul-Nour T, Glatzel U, Lauschke H, Putz U. Evidence for persistence of parvovirus B19 DNA in livers of adults. J Med Virol 2001;65:395-401.
55. Hsu T-C, Tsay GJ, Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:152-7.
56. Cope AP, Jones A, Brozovic M, Shafi MS, Maini RN. Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis 1992;51:803-4.
57. Diaz F, Collazos J, Mendoza F, de la Viuda JM, Cazallas J, Urkijo JC, et al. Systemic lupus erythematosus associated with acute parvovirus B19 infection. Clin Microbiol Infect 2002;8:115-7.
58. Hemauer A, Beckenlehner K, Wolf H, Lang B, Modrow S. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J Clin Virol 1999;14;73-7.
59. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997;72:1-10.
60. Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcome of transfusion patients. Vox Sang 1998;75:97-102.
61. Wakamatsu C, Takakura F, Kojima E, Kiriyama Y, Goto N, Matsumoto K, et al. Screening of blood donors for human parvovirus B19 and characterization of the results. Vox Sang 1999;76:14-23.
62. Kalt M, Gertner E. Antibodies to beta 2-glycoprotein I and cardiolipin with symptoms suggestive of systemic lupus erythematosus in parvovirus B19 infection. J Rheumatol 2001;28;2335-6.
63. Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997;40:103-8.
64. Von Landenberg P, von Landenberg C, Schoelmerich J, Lackner KJ. Antiphospholipid syndrome. Med Klin 2001;15:331-42.
65. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.